Beyond triple-negative breast cancer: The need to define new subtypes

Expert Review of Anticancer Therapy

Volumn 10, Issue 8, 2010, Pages 1197-1213

  Constantinidou, Anastasia ^a   Jones, Robin L ^b   Reis Filho, Jorge S ^c  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b UNIVERSITY OF WASHINGTON   (United States)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

basal like; BRCA1 mutation; subtypes; systemic therapy; triple negative breast cancer

Indexed keywords

BENDAMUSTINE; BEVACIZUMAB; BSI 201; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DASATINIB; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN RECEPTOR; EVEROLIMUS; FLUOROURACIL; GEMCITABINE; MAMMALIAN TARGET OF RAPAMYCIN; NAVELBINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROTEIN KINASE B; TEMSIROLIMUS; TRABECTEDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER GRADING; CANCER RESISTANCE; CLINICAL TRIAL; DNA MICROARRAY; DRUG DOSE COMPARISON; DRUG MEGADOSE; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; LOW DRUG DOSE; ONCOGENE; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; TREATMENT PLANNING; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG DELIVERY SYSTEMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 77956246577     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.50     Document Type: Review

References (124)

1. Cancer Statistics Registrations: Registrations of Cancer Diagnosed in 2006, England. The Office of National Statistics, The Stationery Office, London, UK (2006).
2. Rakha EA, El-Sayed ME, Green AR et al. Prognostic markers in triple-negative breast cancer. Cancer 109(1), 25-32 (2007).
3. Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 13(15 Pt 1), 4429-4434 (2007).
4. Carey LA, Dees EC, Sawyer L et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 13(8), 2329-2334 (2007).
5. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry. Cancer 109(9), 1721-1728 (2007).
6. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology 52(1), 108-118 (2008).
7. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 26(8), 1275-1281 (2008).
8. Gluz O, Nitz UA, Harbeck N et al. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Ann. Oncol. 19(5), 861-870 (2008).
9. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 406(6797), 747-752 (2000).
10. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98(19), 10869-10874 (2001).
11. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100(14), 8418-8423 (2003).
12. Weigelt B, Mackay A, A'Hern R et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol. 11(4), 339-349 (2010).
13. Rouzier R, Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 11(16), 5678-5685 (2005).
14. Pusztai L, Mazouni C, Anderson K, Wu Y, Symmans WF. Molecular classification of breast cancer: limitations and potential. Oncologist 11(8), 868-877 (2006).
15. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N. Engl. J. Med. 360(8), 790-800 (2009).
16. Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J. Pathol. 220(2), 263-280 (2010).
17. Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat. Rev. Clin. Oncol. 6(12), 718-730 (2009).
18. de Ronde JJ, Hannemann J, Halfwerk H et al. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res. Treat. 119(1), 119-126 (2010).
19. Parker JS, Mullins M, Cheang MC et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27(8), 1160-1167 (2009).
20. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J. Clin. Oncol. 26(15), 2568-2581 (2008).
21. Bertucci F, Finetti P, Cervera N et al. How basal are triple-negative breast cancers? Int. J. Cancer 123(1), 236-240 (2008).
22. Cheang MC, Voduc D, Bajdik C et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin. Cancer Res. 14(5), 1368-1376 (2008).
23. Kreike B, van Kouwenhove M, Horlings H et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 9(5), R65 (2007).
24. Rakha EA, Elsheikh SE, Aleskandarany MA et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin. Cancer Res. 15(7), 2302-2310 (2009).
25. Rakha EA, Tan DS, Foulkes WD et al. Are triple-negative tumours and basal-like breast cancer synonymous? Breast Cancer Res. 9(6), 404 (2007).
26. Weigelt B, Horlings HM, Kreike B et al. Refinement of breast cancer classification by molecular characterization of histological special types. J. Pathol. 216(2), 141-150 (2008).
27. Peppercorn J, Perou CM, Carey LA. Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest. 26(1), 1-10 (2008).
28. Farmer P, Bonnefoi H, Becette V et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24(29), 4660-4671 (2005).
29. Chin SF, Teschendorff AE, Marioni JC et al. High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol. 8(10), R215 (2007).
30. Hu Z, Fan C, Oh DS et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7, 96 (2006).
31. Teschendorff AE, Caldas C. A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer. Breast Cancer Res. 10(4), R73 (2008).
32. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol. 8(8), R157 (2007).
33. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to- mesenchymal transition and stem cell characteristics. Cancer Res. 69(10), 4116-4124 (2009).
34. Creighton CJ, Li X, Landis M et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc. Natl Acad. Sci. USA 106(33), 13820-13825 (2009).
35. Jumppanen M, Gruvberger-Saal S, Kauraniemi P et al. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res. 9(1), R16 (2007).
36. Silver DP, Richardson AL, Eklund AC et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J. Clin. Oncol. 28(7), 1145-1153 (2010).
37. Haffty BG, Yang Q, Reiss M et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J. Clin. Oncol. 24(36), 5652-5657 (2006).
38. Tischkowitz M, Brunet JS, Begin LR et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 7, 134 (2007).
39. Foulkes WD, Grainge MJ, Rakha EA, Green AR, Ellis IO. Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status. Breast Cancer Res. Treat. 117(1), 199-204 (2009).
40. Desmedt C, Haibe-Kains B, Wirapati P et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin. Cancer Res. 14(16), 5158-5165 (2008).
41. Wirapati P, Sotiriou C, Kunkel S et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 10(4), R65 (2008).
42. Smid M, Wang Y, Zhang Y et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 68(9), 3108-3114 (2008).
43. Lin NU, Claus E, Sohl J et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 113(10), 2638-2645 (2008).
44. Harris LN, Broadwater G, Lin NU et al. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res. 8(6), R66 (2006).
45. Fulford LG, Reis-Filho JS, Ryder K et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res. 9(1), R4 (2007).
46. Natrajan R, Weigelt B, Mackay A et al. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res. Treat. 121(3), 575-589 (2010).
47. Stephens PJ, McBride DJ, Lin ML et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462(7276), 1005-1010 (2009).
48. Doane AS, Danso M, Lal P et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25(28), 3994-4008 (2006).
49. Turner NC, Reis-Filho JS, Russell AM et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26(14), 2126-2132 (2007).
50. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene 25(43), 5846-5853 (2006).
51. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035), 917-921 (2005).
52. Azoulay S, Lae M, Freneaux P et al. KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. Mod. Pathol. 18(12), 1623-1631 (2005).
53. Lae M, Freneaux P, Sastre-Garau X et al. Secretory breast carcinomas with ETV6- NTRK3 fusion gene belong to the basal-like carcinoma spectrum. Mod. Pathol. 22(2), 291-298 (2009).
54. Lambros MB, Tan DS, Jones RL et al. Genomic profile of a secretory breast cancer with an ETV6-NTRK3 duplication. J. Clin. Pathol. 62(7), 604-612 (2009).
55. Marchio C, Weigelt B, Reis-Filho JS. Adenoid cystic carcinomas of the breast and salivary glands (or 'The Strange Case of Dr. Jekyll and Mr. Hyde' of exocrine gland carcinomas). J. Clin. Pathol. 63(3), 220-228 (2009).
56. Jacquemier J, Padovani L, Rabayrol L et al. Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J. Pathol. 207(3), 260-268 (2005).
57. Vincent-Salomon A, Gruel N, Lucchesi C et al. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res. 9(2), R24 (2007).
58. Reis-Filho JS, Milanezi F, Steele D et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology 49(1), 10-21 (2006).
59. Weigelt B, Kreike B, Reis-Filho JS. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res. Treat. 117(2), 273-280 (2009).
60. Hennessy BT, Giordano S, Broglio K et al. Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann. Oncol. 17(4), 605-613 (2006).
61. Santini D, Ceccarelli C, Taffurelli M, Pileri S, Marrano D. Differentiation pathways in primary invasive breast carcinoma as suggested by intermediate filament and biopathological marker expression. J. Pathol. 179(4), 386-391 (1996)
62. Arnes JB, Brunet JS, Stefansson I et al. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin. Cancer Res. 11(11), 4003-4011 (2005).
63. Fulford LG, Easton DF, Reis-Filho JS et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 49(1), 22-34 (2006).
64. Livasy CA, Karaca G, Nanda R et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod. Pathol. 19(2), 264-271 (2006).
65. Savage K, Leung S, Todd SK et al. Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis. Breast Cancer Res. Treat. 110(2), 245-256 (2008).
66. Tan DS, Marchio C, Jones RL et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res. Treat. 111(1), 27-44 (2008).
67. Kim MJ, Ro JY, Ahn SH et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum. Pathol. 37(9), 1217-1226 (2006).
68. Reis-Filho JS, Steele D, Di Palma S et al. Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue. Mod. Pathol. 19(2), 307-319 (2006).
69. Moyano JV, Evans JR, Chen F et al. aB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J. Clin. Invest. 116(1), 261-270 (2006).
70. Parry S, Savage K, Marchio C, Reis-Filho JS. Nestin is expressed in basal-like and triple negative breast cancers. J. Clin. Pathol. 61(9), 1045-1050 (2008).
71. Klingbeil P, Natrajan R, Everitt G et al. CD44 is overexpressed in basal-like breast cancers but is not a driver of 11p13 amplification. Breast Cancer Res. Treat. 120(1), 95-109 (2010).
72. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 10(16), 5367-5374 (2004).
73. Korsching E, Packeisen J, Agelopoulos K et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab. Invest. 82(11), 1525-1533 (2002).
74. Manie E, Vincent-Salomon A, Lehmann- Che J et al. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res. 69(2), 663-671 (2009).
75. Lakhani SR, Van de Vijver MJ, Jacquemier J et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J. Clin. Oncol. 20(9), 2310-2318 (2002).
76. Nofech-Mozes S, Trudeau M, Kahn HK et al. Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers. Breast Cancer Res. Treat. 118(1), 131-137 (2009).
77. Lakhani SR, Reis-Filho JS, Fulford L et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin. Cancer Res. 11(14), 5175-5180 (2005).
78. Foulkes WD, Stefansson IM, Chappuis PO et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J. Natl Cancer Inst. 95(19), 1482-1485 (2003).
79. van der Groep P, Bouter A, van der Zanden R et al. Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data. J. Clin. Pathol. 59(6), 611-617 (2006).
80. Atchley DP, Albarracin CT, Lopez A et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J. Clin. Oncol. 26(26), 4282-4288 (2008).
81. Liu X, Holstege H, van der Gulden H et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc. Natl Acad. Sci. USA 104(29), 12111-12116 (2007).
82. McCarthy A, Savage K, Gabriel A et al. A mouse model of basal-like breast carcinoma with metaplastic elements. J. Pathol. 211(4), 389-398 (2007).
83. Han W, Jung EM, Cho J et al. DNA copy number alterations and expression of relevant genes in triple-negative breast cancer. Genes Chromosomes Cancer 47(6), 490-499 (2008).
84. Turner N, Lambros MB, Horlings HM et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 29(14), 2013-2023 (2010).
85. Andre F, Job B, Dessen P et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin. Cancer Res. 15(2), 441-451 (2009).
86. Natrajan R, Lambros MB, Rodriguez-Pinilla SM et al. Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin. Cancer Res. 15(8), 2711-2722 (2009).
87. van Beers EH, van Welsem T, Wessels LF et al. Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. Cancer Res. 65(3), 822-827 (2005).
88. Jonsson G, Naylor TL, Vallon-Christersson J et al. Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. Cancer Res. 65(17), 7612-7621 (2005).
89. Waddell N, Arnold J, Cocciardi S et al. Subtypes of familial breast tumours revealed by expression and copy number profiling. Breast Cancer Res. Treat. DOI: 10.1007/s10549-009-0653-1 (2009) (Epub ahead of print).
90. Joosse SA, van Beers EH, Tielen IH et al. Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH. Breast Cancer Res. Treat. 116(3), 479-489 (2009).
91. Matros E, Wang ZC, Lodeiro G et al. BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res. Treat. 91(2), 179-186 (2005).
92. Bartz SR, Zhang Z, Burchard J et al. Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol. Cell. Biol. 26(24), 9377-9386 (2006).
93. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol. 26(22), 3785-3790 (2008).
94. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361(2), 123-134 (2009).
95. Foulkes WD, Metcalfe K, Hanna W et al. Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma. Cancer 98, 1569-1577 (2003).
96. Byrski T, Huzarski T, Dent R et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res. Treat. 115(2), 359-363 (2009).
97. Byrski T, Gronwald J, Huzarski T et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J. Clin. Oncol. 28(3), 375-379 (2010).
98. Gronwald J, Byrski T, Huzarski T et al. Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. J. Clin. Oncol. 27(Suppl. 15s), (2009) (Abstract 502).
99. McCabe N, Turner NC, Lord CJ et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66(16), 8109-8115 (2006).
100. Tutt A, Robson, M., Garber, J.E. et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J. Clin. Oncol. 27(Suppl. 18s), (2009) (Abstract 501).
101. O'Shaughnessy J, Osborne C, Pippen J et al. Efficacy of BSI-201, a poly(ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized Phase II trial. J. Clin. Oncol. 27(Suppl. 18s), (2009) (Abstract 3).
102. Linderholm BK, Hellborg H, Johansson U et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann. Oncol. 20(10), 1639-1646 (2009).
103. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357(26), 2666-2676 (2007).
104. Miles DW, Chan A, Romieu G et al. Final overall survival (OS) results from the randomised, double-blind, placebo-controlled, Phase III AVADO study of bevacizumab (BV) plus docetaxel (D) compared with placebo (PL) plus D for the first-line treatment of locally recurrent (LR) or metastatic breast cancer (mBC). Cancer Res. 69(24), 495S-495S (2009).
105. O'Shaughnessy JA, Brufsky AM. RiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer. Clin. Breast Cancer 8(4), 370-373 (2008).
106. Brufsky A, Bondarenko IN, Smirnov V et al. RIBBON-2: A randomized, double-blind, placebo-controlled, Phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. Cancer Res. 69(24), 495S-496S (2009).
107. Ryan PD, Tung NM, Isakoff SJ et al. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and efficacy. J. Clin. Oncol. 27(Suppl. 15s), (2009) (Abstract 551).
108. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351(4), 337-345 (2004).
109. Carey LA, Rugo HS, Marcom PK et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J. Clin. Oncol. 26(Suppl.), (2008) (Abstract 1009).
110. Finn RS, Dering J, Ginther C et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/'triple-negative' breast cancer cell lines growing in vitro. Breast Cancer Res. Treat. 105(3), 319-326 (2007).
111. Huang F, Reeves K, Han X et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res. 67(5), 2226-2238 (2007).
112. Somlo G, Atzori F, Strauss L et al. Dasatinib plus capecitabine (Cap) for progressive advanced breast cancer (ABC): Phase I study CA180004. J. Clin. Oncol. 27(Suppl.), (2009) (Abstract 1012).
113. Mirzoeva OK, Das D, Heiser LM et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res. 69(2), 565-572 (2009).
114. Marty B, Maire V, Gravier E et al. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res. 10(6), R101 (2008).
115. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 68(15), 6084-6091 (2008).
116. Vasudevan KM, Barbie DA, Davies MA et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16(1), 21-32 (2009).
117. Iorns E, Lord CJ, Grigoriadis A et al. Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PLoS ONE 4(4), e5120 (2009).
118. Ozaki K, Kishikawa F, Tanaka M et al. Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs. Cancer Sci. 99(2), 376-384 (2008).
119. Caldas-Lopes E, Cerchietti L, Ahn JH et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc. Natl Acad. Sci. USA 106(20), 8368-8373 (2009).
120. Rahman M, Davis SR, Pumphrey JG et al. TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res. Treat. 113(2), 217-230 (2009).
121. Neve RM, Chin K, Fridlyand J et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10(6), 515-527 (2006).
122. Greenman C, Stephens P, Smith R et al. Patterns of somatic mutation in human cancer genomes. Nature 446(7132), 153-158 (2007).
123. Stephens P, Edkins S, Davies H et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat. Genet. 37(6), 590-592 (2005).
124. Aparicio SA, Huntsman DG. Does massively parallel DNA resequencing signify the end of histopathology as we know it? J. Pathol. 220(2), 307-315 (2009).